現在の所属組織 【 表示 ／ 非表示 】

現在の所属組織 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

職歴 【 表示 ／ 非表示 】

職歴 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer.

  Katsunori Tanaka, Hitoshi Hirakawa, Mikio Suzuki, Teruyuki Higa, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Masatomo Toyama, Tomoyo Higa, Hidetoshi Kinjyo, Norimoto Kise, Shunsuke Kondo, Hiroyuki Maeda, Taro Ikegami

  Current oncology (Toronto, Ont.)   30 ( 6 ) 5409 - 5424   2023年06月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that can predict the anti-PD-1 antibody treatment effect and immune-related adverse events (irAEs) in these patients. This study investigated the inflammatory and nutritional status in 42 patients with R/M-HNSCC and programmed cell death ligand-1 (PD-L1) polymorphisms (rs4143815 and rs2282055) in 35 of the 42 patients. The 1- and 2-year overall survival was 59.5% and 28.6%, respectively; the 1- and 2-year first progression-free survival was 19.0% and 9.5%, respectively, and the respective second progression-free survival was 50% and 27.8%. Performance status and inflammatory and nutritional status (assessed by the geriatric nutritional risk index, modified Glasgow prognostic score, and prognostic nutritional index) were identified as significant indicators of survival outcomes in multivariate analysis. Patients with ancestral alleles in PD-L1 polymorphisms had less frequent irAEs. Performance status and inflammatory and nutritional status before treatment were closely related to survival outcomes after PD-1 therapy. These indicators can be calculated using routine laboratory data. PD-L1 polymorphisms may be biomarkers for predicting irAEs in patients receiving anti-PD-1 therapy.

  • この論文にアクセスする
    DOI
  • 関連情報を調べる
    PubMed

• Human papillomavirus infection and EGFR exon 20 insertions in sinonasal inverted papilloma and squamous cell carcinoma

  Hitoshi Hirakawa, Taro Ikegami, Norimoto Kise, Hidetoshi Kinjyo, Shunsuke Kondo, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Hiroyuki, Maeda, Mikio Suzuki

  Journal of Personalized Medicine   13 ( 4 ) 657   2023年04月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  • この論文にアクセスする
    DOI

• Nivolumabの治療効果および安全性に対するバイオマーカーについての検討

  田中 克典, 真栄田 裕行, 平川 仁, 安慶名 信也, 上里 迅, 金城 秀俊, 鈴木 幹男

  日本気管食道科学会会報 ( (NPO)日本気管食道科学会 )  74 ( 2 ) s13 - s13   2023年04月 [ 査読有り ]

  掲載種別: 研究論文（その他学術会議資料等）

• p16 Overexpression in Sinonasal Squamous Cell Carcinoma: Association with Human Papillomavirus and Prediction of Survival Outcomes

  Hitoshi Hirakawa , Taro Ikegami, Mikio Suzuki

  Journal of Clinical Medicine     2023年 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

• Prospective Analysis of Squamous Cell Carcinoma Antigen-1 and -2 for Diagnosing Sinonasal Inverted Papilloma

  Katsunori Tanaka, Hitoshi Hirakawa, Mikio Suzuki, Taro Ikegami

  Current Oncology ( MDPI )  ( 30 ) 5409 - 5424   2023年 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

全件表示 >>